Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The cost of unresectable stage III or stage IV melanoma in Italy.

Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C.

J Exp Clin Cancer Res. 2012 Nov 1;31:91. doi: 10.1186/1756-9966-31-91.

2.

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, Testori A, Bédane C, Konto C, Dueymes A, Sbarigia U, van Baardewijk M.

Eur J Cancer. 2012 Sep;48(14):2175-82. doi: 10.1016/j.ejca.2012.03.003. Epub 2012 Apr 3.

PMID:
22480965
3.

Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD.

Appl Health Econ Health Policy. 2009;7(1):31-41. doi: 10.2165/00148365-200907010-00004.

PMID:
19558193
4.

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).

Lebbe C, Lorigan P, Ascierto P, Testori A, Bédane C, Middleton M, van Baardewijk M, Konto C, Dueymes A, Maio M.

Eur J Cancer. 2012 Nov;48(17):3205-14. doi: 10.1016/j.ejca.2012.05.010. Epub 2012 Jun 27.

PMID:
22742880
5.
6.

An estimate of the annual direct cost of treating cutaneous melanoma.

Tsao H, Rogers GS, Sober AJ.

J Am Acad Dermatol. 1998 May;38(5 Pt 1):669-80.

PMID:
9591809
7.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
8.

Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.

Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC.

Arch Dermatol. 2010 Mar;146(3):249-56. doi: 10.1001/archdermatol.2009.389.

PMID:
20231494
9.

Multicohort model for prevalence estimation of advanced malignant melanoma in the USA: an increasing public health concern.

Lin AY, Wang PF, Li H, Kolker JA.

Melanoma Res. 2012 Dec;22(6):454-9. doi: 10.1097/CMR.0b013e328358d96f.

PMID:
22990665
10.

Malignant melanoma in Turkey: a single institution's experience on 475 cases.

Tas F, Kurul S, Camlica H, Topuz E.

Jpn J Clin Oncol. 2006 Dec;36(12):794-9. Epub 2006 Oct 23.

PMID:
17060409
11.

Treatment patterns and outcomes in patients with advanced melanoma in France.

Bedane C, Leccia MT, Sassolas B, Bregman B, Lebbé C; French investigators of the MELODY study.

Curr Med Res Opin. 2013 Oct;29(10):1297-305. doi: 10.1185/03007995.2013.820693. Epub 2013 Jul 26.

PMID:
23808961
12.

Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.

Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalac S, Truchetet F, Michel C, Batard ML, Baury B, Halna JM, Schmutz JL, Delvincourt C, Reuter G, Dalle S, Bernard P, Danzon A.

Arch Dermatol. 2008 May;144(5):629-36. doi: 10.1001/archderm.144.5.629.

PMID:
18490589
13.

Cost-effectiveness of reduced follow-up in malignant melanoma.

Hengge UR, Wallerand A, Stutzki A, Kockel N.

J Dtsch Dermatol Ges. 2007 Oct;5(10):898-907. English, German.

PMID:
17910672
14.

Epidemiology and clinical and pathologic characteristics of cutaneous malignant melanoma in Abruzzo (Italy).

Amerio P, Manzoli L, Auriemma M, Carbone A, Proietto G, Angelucci D, Tulli A.

Int J Dermatol. 2009 Jul;48(7):718-22. doi: 10.1111/j.1365-4632.2009.03974.x.

PMID:
19570077
15.

Investment in new technology research can save future health care dollars.

Reintgen D, Albertini J, Milliotes G, Marshburn J, Cruse CW, Rapaport D, Berman C, Glass F, Fensske N, Einstein AB Jr, Lyman G.

J Fla Med Assoc. 1997 Mar;84(3):175-81.

PMID:
9143169
16.

Stage-specific direct health care costs in patients with cutaneous malignant melanoma.

Lyth J, Carstensen J, Synnerstad I, Lindholm C.

J Eur Acad Dermatol Venereol. 2016 May;30(5):789-93. doi: 10.1111/jdv.13110. Epub 2015 Mar 23.

PMID:
25807966
17.

Biology of desmoplastic melanoma: a case-control comparison with other melanomas.

Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm MC Jr, Michaelson JS, Cosimi AB, Tanabe KK.

J Clin Oncol. 2005 Sep 20;23(27):6739-46.

PMID:
16170181
18.

The economic burden of melanoma in France: assessing healthcare use in a hospital setting.

Chevalier J, Bonastre J, Avril MF.

Melanoma Res. 2008 Feb;18(1):40-6. doi: 10.1097/CMR.0b013e3282f36203.

PMID:
18227707
19.

Nodular melanoma in 62 Japanese patients: influence of initial surgical treatment on local recurrence and prognosis.

Kato T, Suetake T, Kumasaka N, Tabata N, Sugiyama Y, Tagami H.

J Dermatol. 1995 Oct;22(10):723-8.

PMID:
8586749
20.

A retrospective study of 304 cases of malignant melanoma in Malmö 1952-71.

Mattsson W, Gynning I, Hogeman KE, Jacobsson S, Linell F.

Scand J Plast Reconstr Surg. 1976;10(3):189-95.

PMID:
1053448

Supplemental Content

Support Center